Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05720663 · ClinicalTrials.gov registry record
Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
A clinical trial of Nonalcoholic Steatohepatitis, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- 240
- Enrollment target
- 2
- Study locations
NCT05720663 is a study of Nonalcoholic Steatohepatitis that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 240 participants, below the 1,016-participant average among 17 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05720663, a study of Nonalcoholic Steatohepatitis, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- 240 participants
- Enrollment target
- 2
- Study locations
Study Summary
Nonalcoholic Steatohepatitis (NASH) is a condition with increased amount of fat, inflammation and scarring in the liver. In compensated cirrhosis, the liver is coping with this damage and maintaining its important functions. Decompensation occurs when the liver becomes unable to perform all of its functions adequately. Variceal hemorrhage (bleeding from abnormal vessels in the liver called varices), Ascites (abnormal build-up of fluid in the abdomen), and Encephalopathy (brain confusion as a result of the liver not being able to get rid of toxic substances) are three symptoms of liver decompensation. The purpose of this research study is to investigate better ways to routinely monitor the condition of patients with NASH with compensated cirrhosis and to better pinpoint the development of decompensation in the livers of these patients.
Conditions Studied
Interventions
- OTHER Standard of care
Study Locations (2)
Minnesota
- Mayo Clinic in Rochester - Rochester
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2023-04-19 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05720663
The ClinicalTrials.gov registry entry for NCT05720663 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,016-participant average among 17 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (76% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 1 intervention - of which Standard of care is the first listed.
NCT05720663 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Virginia.
Frequently Asked Questions
What is clinical trial NCT05720663 about?
NCT05720663 is a clinical study titled "Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis". Nonalcoholic Steatohepatitis (NASH) is a condition with increased amount of fat, inflammation and scarring in the liver. In compensated cirrhosis, the liver is coping with this damage and maintaining its important functions. Decompensation occurs when the liver becomes unable to perform all of its f...
What is the current status of trial NCT05720663?
This trial is currently recruiting. The enrollment target is 240 participants. The study started on 2023-04-19. Estimated completion is 2027-12.
What conditions does trial NCT05720663 study?
This clinical trial studies the following conditions: Nonalcoholic Steatohepatitis.
What interventions are being tested in trial NCT05720663?
The interventions under investigation include: Standard of care (OTHER).
Who is sponsoring clinical trial NCT05720663?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05720663 being conducted?
This trial has 2 study locations across Minnesota, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
RECRUITING · Phase 2
-
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
RECRUITING
-
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
RECRUITING · Phase 2
-
Metabolic Pathology of Pediatric NAFLD
RECRUITING · NA
-
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.